文献速递胸部肿瘤

表皮生长因子受体膜/胞质/核转位诱导酪氨酸激酶抑制剂耐药的分子机制

Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
PubMed 文献 · J Thorac Oncol · 2019-06-19

研究探讨肺腺癌中EGFR膜/胞质/核转位与TKI耐药的关系。膜性突变EGFR患者经吉非替尼治疗后无进展生存期显著长于胞质性突变者。第一代TKI耐药诱导过程中膜EGFR转位至胞质/核并伴Hippo通路抑制;奥希替尼诱导的耐药也见EGFR转位但无Hippo通路抑制。

要点

  • 膜性突变EGFR(19del或21 L858R)晚期肺腺癌患者吉非替尼治疗后无进展生存期显著长于胞质性突变者。
  • 胞质EGFR与SIK2相互作用抑制LATS1与MST1结合,促进YAP核转位。
  • 奥希替尼与厄洛替尼在耐药细胞中可相互恢复敏感性。

核心结论

  • EGFR浆/核转位和Hippo通路抑制是第一代TKI诱导耐药的重要机制之一。
  • 奥希替尼诱导的EGFR膜/浆转位可能是除c-MET扩增、C797S突变和ERK通路抑制之外的另一种耐药现象。

研究设计与样本

  • 对TKI治疗后的肺腺癌标本行免疫组化检测EGFR分布,分析不同EGFR定位与患者生存时间的关系。
  • 采用质谱分析和免疫沉淀显示胞质EGFR与YAP及SIK2的相互作用。
  • 采用双荧光素酶试验、免疫印迹、实时聚合酶链反应和功能实验阐明EGFR胞质/核转位在Hippo通路失调中的作用。

主要发现

  • 晚期肺腺癌中膜性突变EGFR(19del或21 L858R)患者吉非替尼治疗后的无进展生存期显著长于胞质性突变EGFR患者。
  • 胞质EGFR的PC-9细胞半数抑制浓度高于膜性EGFR的人非小细胞肺癌827细胞。
  • 第一代TKI耐药诱导过程中,膜EGFR转位至胞质/核,伴随Hippo通路抑制。
  • 胞质EGFR与SIK2相互作用抑制LATS1与MST1相互作用,促进YAP核转位。
  • 奥希替尼诱导耐药的细胞也显示EGFR转位和磷酸化EGFR降低,但未显示Hippo通路抑制;奥希替尼和厄洛替尼在耐药细胞中可相互恢复敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The molecular mechanism underlying the induction of resistance to tyrosine kinase inhibitors (TKIs) via the membranous/cytoplasmic/nuclear translocation of EGFR has not yet been reported. METHODS: We performed immunohistochemistry to detect the distribution of EGFR in lung adenocarcinoma specimens after TKI treatment and analyzed the relationship between different EGFR locations and patient survival duration. Mass spectrometry analysis and immunoprecipitation were performed to show the interaction of cytosolic EGFR with YY1 associated protein 1 (YAP) and salt inducible kinase 2 (SIK2). Dual-luciferase assays, immunoblotting, real-time polymerase chain reaction, and functional experiments were used to elucidate the role of EGFR cytoplasmic/nuclear translocation in Hippo pathway dysregulation. RESULTS: Patients with advanced lung adenocarcinoma with membranous mutant EGFR (19del or 21 L858R) showed significantly longer progression-free survival than those with cytoplasmic mutant EGFR after gefitinib treatment. The concentration that inhibits 50% in PC-9 with cytoplasmic EGFR was higher than that in hunman non-small cell lung cancer 827 with membranous EGFR. During first-generation TKI resistance induction, membrane EGFR translocated to the cytoplasm/nucleus, accompanied by the Hippo pathway inhibition. Cytoplasmic EGFR and SIK2 interaction inhibited large tumor suppressor kinase 1 (LATS1) and macrophage stimulating 1 (MST1) interaction, promoting YAP nuclear translocation. However, cells with osimertinib-induced resistance also showed EGFR translocation and lower phospho-EGF receptor but did not show Hippo pathway inhibition. Moreover, osimertinib and erlotinib could restore sensitivity to each other in resistant cells. CONCLUSIONS: Plasma/nuclear translocation of EGFR and inhibition of the Hippo pathway are some of the important mechanisms underlying the resistance induced by first-generation TKIs. Membrane/plasma translocation of EGFR induced by osimertinib may be another resistance phenomenon besides MNNG HOS transforming gene (c-MET) amplification, C797S mutation, and ERK pathway inhibition.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rong X, Liang Y, Han Q, et al. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. J Thorac Oncol. 2019. PMID: 31228625. doi:10.1016/j.jtho.2019.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。